Scientific rationale for specific inhibition of COX-2

Journal of Rheumatology

Volumn 25, Issue SUPPL. 51, 1998, Pages 2-7

  Bolten, Wolfgang W ^a  

^a Rheumaklinik Wiesbaden   (Germany)

Author keywords

CYCLOOXYGENASE; NONSTEROIDAL ANTIINFLAMMATORY DRUG; PROSTAGLANDIN

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; ISOENZYME; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; MEMBRANE PROTEIN; PEROXIDASE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CONFERENCE PAPER; DRUG DESIGN; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME POLYMORPHISM; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; MOLECULAR CLONING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; ENZYMOLOGY; METABOLISM; REVIEW; RHEUMATIC DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PEROXIDASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RHEUMATIC DISEASES;

EID: 0031921289     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (84)

1. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
2. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119;257-62.
3. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;115:787-96.
4. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk models. Am J Med 1991;91:213-22.
5. Pincus T, Griffin M. Gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs: new insights from observational studies and functional status questionnaires. Am J Med 1991;91:209-12.
6. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs [published erratum appears in Lancet 1994;343:1048]. Lancet 1994;343:769-72.
7. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. Rheumatol 1991;28 Suppl:6-10.
8. Hudson N, Hawkey CJ. Non-steroidal anti-inflammatory drug-associated upper gastrointestinal ulceration and complications. Eur J Gastroenterol Hepatol 1993;5:412-9.
9. Wolfe F. The epidemiology of NSAID associated gastrointestinal disease. Eur J Rheumatol Inflamm 1991;11:12-28.
10. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs: report of four cases and review of the literature. Arch Intern Med 1992;152:625-32.
11. Tanner AR, Raghunath AS. Colonic inflammation and nonsteroidal anti-inflammatory drug administration: an assessment of the frequency of the problem. Digestion 1988;41:116-20.
12. Allison MC, Howatson AG, Torrance CJ, Lee FE, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749-54.
13. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971;231:232-5.
14. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
15. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS 10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992;267:4338-44.
16. Regier MK, DeWitt DL, Schindler MS, Smith WL. Subcellular localisation of prostaglandin endoperoxide synthase-2 in murine 3T3 cells. Arch Biochem Biophys 1993;301:439-44.
17. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384-8.
18. Xie W, Chapman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
19. Feng L, Sun W, Xia Y, et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993;307:361-8.
20. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum and glucocorticoid regulated 4-kilobase mRNA encodes a cyclooxygenase related protein. J Biol Chem 1991;266:23261-7.
21. Kujubu DA, Herschman HR. Dexamethasone inhibits nitrogen induction of the TIS10 prostaglandin synthase/cyclo-oxygenase gene. J Biol Chem 1992;267:7991-4.
22. Sirois J, Richards JS. Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992;267:6382-8.
23. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Devel Res 1992;25:249-65.
24. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem 1986;55:69-102.
25. Yamamoto S. Biology and chemistry of prostaglandins and related eicosanoids. In: Curtis-Prior PB, editor. Prostaglandins: Biology and chemistry of prostaglandins and related eicosanoids. London: Churchill Livingstone; 1988:37-45.
26. Smith WL, DeWitt DL, Karaemer SA, et al. Structure-function relationships in sheep, mouse and human prostaglandin endoperoxide G/H synthases. Adv Prostaglandin Thromboxane Leukot Res 1990;20:14-21.
27. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5.
28. Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980;284:271-3.
29. Moore PK. Prostanoids and the kidney. In: Moore PK, editor. Prostanoids: pharmacological, physiological, and clinical relevance. New York: Cambridge University Press; 1985:173-99.
30. Quilley J, McGriff JC. Renal arachidonic acid metabolism. In: Hushka PV, Mais DE, editors. Eicosanoids in the cardiovascular and renal systems. Norwell, Mass: MTP Press; 1988:16-33.
31. Weksler BB, Eldor A, Falcone D, Levin RI, Jaffe EA, Minick CR. Prostaglandins and vascular endothelium. In: Herman AG, Vanhoutte PM, Denolin H, Goossens A, editors. Cardiovascular pharmacology of the prostaglandins. New York: Raven Press; 1982:137-48.
32. Cromwell O. Contribution of eicosanoids to the immediate and late inflammatory responses. In: Church M, Robinson C, editors. Eicosanoids in inflammatory conditions of the lung, skin and joints. Norwell, Mass: MTP Press; 1988:21-42.
33. Zurier RB. Prostaglandins and inflammation. In: Curtis-Prior PB, editor. Prostaglandins: biology and chemistry of prostaglandins and related eicosanoids. New York: Churchill Livingstone; 1988: 595-607.
34. DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993;95:40-6.
35. DeWitt DL. Prostaglandin endoperoxidase synthase: regulation of enzyme expression. Biochem Biophys Acta 1991;1083:121-34.
36. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-92.
37. Jones DA, Carlton CP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxidase synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-54.
38. Ryseck RP, Raynoschek C, Macdonald-Bravoy H, Dorfman K, Mattel M-G, Bravo R. Identification of an immediate early gene, pghs-B, whose protein product has prostaglandin synthase/cyclooxygenase activity. Cell Growth Differ 1992;3: 443-50.
39. Hempel SL, Monick MM, Hunninghake GW. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 1994;93:391-6.
40. DuBois RN, Awad J, Morrow J, Roberts LJ II, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 1994;93:493-8.
41. Sirois J, Levy L, Simmons DL, Richards JS. Characterization and hormonal regulation of the promoter of the rat prostaglandin endoperoxidase synthase 2 gene in granulosa cells. J Biol Chem 1993;268:12199-206.
42. Sirois J, Simmons DL, Richards JS. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxidase H synthase in rat preovulatory follicles. J Biol Chem 1993;267:11586-92.
43. Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-8.
44. O'Sullivan MG, Chilton FH, Huggins EM Jr, McCall CE. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J Biol Chem 1992;267:14547-50.
45. Kennedy BP, Chan CC, Culp SA, Cromlish WA. Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem Biophys Res Commun 1993;197:494-500.
46. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-40.
47. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86;1375-9.
48. Crofford LJ, Wilder RL, Ristimäki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effect of interleukin 1b, phorbol esters, and corticosteroids. J Clin Invest 1994;93: 1095-101.
49. Kang RY, Freire-Moar J, Sigal E, Chu C-Q. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996;35:711-8.
50. Cush JJ, Lipsky PE. The immunopathogenesis of rheumatoid arthritis: the role of cytokines in chronic inflammation. Clin Aspects Autoimmun 1987;1:2-13.
51. Salmon JA, Higgs GA, Vane JR, et al. Synthesis of arachidonate cyclooxygenase products by rheumatoid and nonrheumatoid synovial lining in nonproliferative organ culture. Ann Rheum Dis 1983;42:36-9.
52. Vane J. Towards a better aspirin. Nature 1994;367:215-6.
53. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxidase synthase (cyclooxygenase) isoenzyme by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
54. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-7.
55. Morham SC, Langenbach R, Loftin CD, et al. Prostaglandin synthase-2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-82.
56. Tippetts MT, Varnum BC, Lim RW, Herschman HR. Tumor promoter-inducible genes are differentially expressed in the developing mouse. Mol Cell Biol 1988;8:4570-2.
57. Smith WL, Gutekunst DI, Lyons RII Jr. Immunocytochemical localization of the prostaglandin-forming cyclooxygenase in the cerebral cortex. Prostaglandins 1980;19:61-9.
58. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371-86.
59. Beiche F, Scheurer S, Brune K, Geisslinger G, Goppelt-Struebe M. Upregulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996;390:165-9.
60. Bredder CD, DeWitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995;355:296-315.
61. Akai Y, Homma T, Burns KD, Yasuda T, Badr KR, Harris RC. Mechanical stretch/relaxation of cultured rat mesangial cells induces protooncogenes and cyclooxygenase. Am J Physiol 1994;267(2Pt 1):C482-90.
62. Jacobs AL, Hwang D, Julian J, Carson DD. Regulated expression of prostaglandin endoperoxide synthase-2 by uterine stroma. Endocrinology 1994;135:1807-15.
63. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996;97:2672-9.
64. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
65. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide II synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-34.
66. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX-2 inhibitors. Inflamm Res 1995;44:253-7.
67. Engelhardt G, Bögel R, Schnitzer C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism; part I: in vitro findings. Biochem Pharmacol 1996;51:21-8.
68. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
69. Boyce S, Chan C-C, Gordon R, et al. L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats. Neuropharmacology 1994;33:1609-11.
70. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
71. Vane JR, Botting RM. New insights into the mode of action of antiinflammatory drugs. Inflamm Res 1995;44:1-10.
72. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-71.
73. Inman HW, Wilton LV, Pearce GL, Waller PC. Prescription-event monitoring of nabumetone. Pharmaceut Med 1990;4:309-17.
74. Pairet M, Churchill L, Engelhardt G. Differential inhibition of cyclooxygenase 1 and 2 by NSAIDs. In: Brazan N, Botting J, Vane J, editors. New targets in inflammation. Inhibitors of COX-2 or adhesion molecules. Dordrecht, Netherlands: Kluwer Academic Publishers; 1996:23-38.
75. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996;35 Suppl 1:39-43.
76. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996;35 Suppl 1:35-8.
77. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35 Suppl 1: 68-77.
78. Chikanza IC, Clarke B, Hopkins R, MacFarlane DG, Bird H, Grahame R. A comparative study of the efficacy and toxicity of etodolac and naproxen in the treatment of osteoarthritis. Br J Clin Pract 1994;48:67-9.
79. Leese P. Comparison of the effects of etodolac SR and naproxen on gastro-intestinal blood loss. Curr Med Res Opin 1992;13:13-20.
80. Glaser K, Sung M-L, Belfast M, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995;281:107-11.
81. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995;42:428-33.
82. Taha AS, McLaughlin S, Holland PJ, Kelly RW, Sturrock RD, Russell RI. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. Ann Rheum Dis 1990;49:354-8.
83. Griswold DE, Adams JL. Constitutive cyclooxygenase (cox-1) and inducible cyclooxygenase (cox-2): rationale for selective inhibition and progress to date [review]. Med Res Rev 1996;16:181-206.
84. McKenna F. Diclofenac/Misoprostol: The European clinical experience. J Rheumatol 1998;25 Suppl 51:21-30.